Cantargia: Negative TNBC Survival Data, as Expected - Redeye
Bildkälla: Stockfoto

Cantargia: Negative TNBC Survival Data, as Expected - Redeye

Redeye comments on the survival readout in the phase IIb study TRIFOUR, which investigates nadunolimab + chemotherapy in triple-negative breast cancer.

Redeye comments on the survival readout in the phase IIb study TRIFOUR, which investigates nadunolimab + chemotherapy in triple-negative breast cancer.
Börsvärldens nyhetsbrev